10 March 2016
We represented the shareholders of Genable Technologies Limited, an Irish privately held venture-capital backed biopharmaceutical company, on the sale of the company to Spark Therapeutics Inc., a NASDAQ listed leading US gene therapy company.
The consideration paid to Genable shareholders consisted of $6 million in cash and 265,000 shares of Spark common stock.
This transaction will ensure the expedient clinical development of Genable’s RhoNova™ for the treatment of autosomal dominant rhodopsin linked retinitis pigmentosa, a leading cause of inherited blindness
Mason Hayes & Curran have acted for Genable since the company was spun out of TCD in 2004, helping the business to raise funding and enter into collaborations, including with Spark Therapeutics, to develop RhoNova™.